Logo image of CELL

PHENOMEX INC (CELL) Stock Fundamental Analysis

NASDAQ:CELL - Nasdaq - US0843101017 - Common Stock - Currency: USD

0.9981  +0 (+0.31%)

After market: 0.999 +0 (+0.09%)

Fundamental Rating

3

Taking everything into account, CELL scores 3 out of 10 in our fundamental rating. CELL was compared to 55 industry peers in the Life Sciences Tools & Services industry. While CELL seems to be doing ok healthwise, there are quite some concerns on its profitability. CELL is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CELL has reported negative net income.
CELL had a negative operating cash flow in the past year.
In the past 5 years CELL always reported negative net income.
CELL had a negative operating cash flow in each of the past 5 years.
CELL Yearly Net Income VS EBIT VS OCF VS FCFCELL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 -20M -40M -60M -80M

1.2 Ratios

CELL has a Return On Assets of -69.85%. This is amonst the worse of the industry: CELL underperforms 92.19% of its industry peers.
CELL has a worse Return On Equity (-111.90%) than 87.50% of its industry peers.
Industry RankSector Rank
ROA -69.85%
ROE -111.9%
ROIC N/A
ROA(3y)-27.59%
ROA(5y)-23.81%
ROE(3y)-40.38%
ROE(5y)-34.8%
ROIC(3y)N/A
ROIC(5y)N/A
CELL Yearly ROA, ROE, ROICCELL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 -20 -40 -60

1.3 Margins

With an excellent Gross Margin value of 64.75%, CELL belongs to the best of the industry, outperforming 89.06% of the companies in the same industry.
In the last couple of years the Gross Margin of CELL has declined.
CELL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 64.75%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.73%
GM growth 5YN/A
CELL Yearly Profit, Operating, Gross MarginsCELL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 0 50 -50 -100

More info and screens

5

2. Health

2.1 Basic Checks

CELL does not have a ROIC to compare to the WACC, probably because it is not profitable.
CELL has more shares outstanding than it did 1 year ago.
The debt/assets ratio for CELL is higher compared to a year ago.
CELL Yearly Shares OutstandingCELL Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 20M 40M 60M
CELL Yearly Total Debt VS Total AssetsCELL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -3.61, we must say that CELL is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of CELL (-3.61) is worse than 85.94% of its industry peers.
CELL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.61
ROIC/WACCN/A
WACC11.88%
CELL Yearly LT Debt VS Equity VS FCFCELL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 100M 200M

2.3 Liquidity

CELL has a Current Ratio of 2.25. This indicates that CELL is financially healthy and has no problem in meeting its short term obligations.
CELL has a Current ratio of 2.25. This is in the lower half of the industry: CELL underperforms 70.31% of its industry peers.
A Quick Ratio of 1.26 indicates that CELL should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.26, CELL is doing worse than 75.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.25
Quick Ratio 1.26
CELL Yearly Current Assets VS Current LiabilitesCELL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for CELL have decreased by -9.52% in the last year.
Looking at the last year, CELL shows a very negative growth in Revenue. The Revenue has decreased by -17.32% in the last year.
Measured over the past years, CELL shows a quite strong growth in Revenue. The Revenue has been growing by 11.51% on average per year.
EPS 1Y (TTM)-9.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.53%
Revenue 1Y (TTM)-17.32%
Revenue growth 3Y11.51%
Revenue growth 5YN/A
Sales Q2Q%-26.58%

3.2 Future

Based on estimates for the next years, CELL will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.95% on average per year.
CELL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.33% yearly.
EPS Next Y17.97%
EPS Next 2Y25.78%
EPS Next 3Y21.68%
EPS Next 5Y15.95%
Revenue Next Year-10.41%
Revenue Next 2Y9.31%
Revenue Next 3Y15.99%
Revenue Next 5Y20.33%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CELL Yearly Revenue VS EstimatesCELL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M
CELL Yearly EPS VS EstimatesCELL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 -0.5 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CELL. In the last year negative earnings were reported.
Also next year CELL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CELL Price Earnings VS Forward Price EarningsCELL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CELL Per share dataCELL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

CELL's earnings are expected to grow with 21.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.78%
EPS Next 3Y21.68%

More info and screens

0

5. Dividend

5.1 Amount

CELL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PHENOMEX INC

NASDAQ:CELL (9/29/2023, 8:22:41 PM)

After market: 0.999 +0 (+0.09%)

0.9981

+0 (+0.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-14 2023-08-14/amc
Earnings (Next)11-06 2023-11-06/amc
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners0.13%
Ins Owner Change0%
Market Cap98.79M
Analysts50.91
Price Target1.53 (53.29%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-2.91%
Min EPS beat(2)-4.8%
Max EPS beat(2)-1.01%
EPS beat(4)0
Avg EPS beat(4)-15.27%
Min EPS beat(4)-49.99%
Max EPS beat(4)-1.01%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-9.51%
Min Revenue beat(2)-20.56%
Max Revenue beat(2)1.55%
Revenue beat(4)1
Avg Revenue beat(4)-12.68%
Min Revenue beat(4)-28.89%
Max Revenue beat(4)1.55%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-73.53%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.38
P/FCF N/A
P/OCF N/A
P/B 0.89
P/tB 1.11
EV/EBITDA N/A
EPS(TTM)-1.38
EYN/A
EPS(NY)-0.6
Fwd EYN/A
FCF(TTM)-0.69
FCFYN/A
OCF(TTM)-0.67
OCFYN/A
SpS0.73
BVpS1.12
TBVpS0.9
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -69.85%
ROE -111.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 64.75%
FCFM N/A
ROA(3y)-27.59%
ROA(5y)-23.81%
ROE(3y)-40.38%
ROE(5y)-34.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.73%
GM growth 5YN/A
F-Score3
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.53%
Cap/Sales 2.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.25
Quick Ratio 1.26
Altman-Z -3.61
F-Score3
WACC11.88%
ROIC/WACCN/A
Cap/Depr(3y)145.66%
Cap/Depr(5y)157.52%
Cap/Sales(3y)11.31%
Cap/Sales(5y)14.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.53%
EPS Next Y17.97%
EPS Next 2Y25.78%
EPS Next 3Y21.68%
EPS Next 5Y15.95%
Revenue 1Y (TTM)-17.32%
Revenue growth 3Y11.51%
Revenue growth 5YN/A
Sales Q2Q%-26.58%
Revenue Next Year-10.41%
Revenue Next 2Y9.31%
Revenue Next 3Y15.99%
Revenue Next 5Y20.33%
EBIT growth 1Y-16.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year7.51%
EBIT Next 3Y18.4%
EBIT Next 5YN/A
FCF growth 1Y-50.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-70.31%
OCF growth 3YN/A
OCF growth 5YN/A